Cancer Stem Cells and Personalized Medicine for Gynecologic Cancers

Dear Colleagues,

This Special Issue will focus on cancer stem cells (CSCs) and gynecologic cancers. CSCs retain the ability to renew themselves and lead to the heterogeneity of tumors, which are similar to stem cells. As leading causes of death that endanger women’s reproductive health, uterine cancer, ovarian cancer, and cervical cancer are characterized by high degree of malignancy, metastasis, and recurrence. CSCs are closely connected with these characteristics. CSCs represent a major concern for current cancer treatment and intervention strategies. The potential of CSC to play an important role in personalized/precision medicine is emerging and worthy of study.

I would like to invite leaders in the field to discuss the identification and characteristics of uterine, ovarian, and cervical CSCs. Secondly, I would like to invite leaders in the field to discuss new treatment strategies that could target CSCs, alone and in combination with classic chemotherapeutic agents, biological therapies, or immunotherapies, with the goal of taking approaches from the bench to the clinic. Authors should discuss the latest technological advances in these studies and how CSCs fit in the new paradigms of personalized medicine for gynecologic cancers and precision therapy approaches for uterine, ovarian, and cervical cancers. This Special Issue will not only summarize the roles of CSCs in the genesis, development, drug resistance, metastasis, and recurrence of uterine cancer, ovarian cancer, and cervical cancer, but also propose potential novel treatment and intervention approaches in the hope of inspiring readers and researchers throughout the world.

Prof. Dr. Kenneth P Nephew
Prof. Dr. Daniela Matei
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.